Gabriel H Hortobagyi

Learn More
Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for male breast cancer is not known. This article summarizes a multidisciplinary international meeting on male(More)
BACKGROUND Invasive disease-free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph node-negative (LN-) tumors with a 21-gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes(More)
Forty-two patients with metastatic breast carcinoma previously treated with a combination of cyclophosphamide, methotrexate, and 5-FU, with or without vincristine or prednisone, were treated at relapse with a sequential combination of doxorubicin and vinblastine given by continuous infusion. Two patients achieved complete remission and 16 achieved partial(More)
  • 1